Trials / Completed
CompletedNCT01369472
Evaluating Dose-proportionality of Dilatrend Suspended-Release Capsule
A Randomized, Open-label, Single Dose, Dose-rising 10-sequence, 3-period Balanced Incomplete Blocked Clinical Trial to Evaluate Dose-proportionality of Dilatrend SR in Healthy Male Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- Sponsor
- Chong Kun Dang Pharmaceutical · Industry
- Sex
- Male
- Age
- 20 Years – 54 Years
- Healthy volunteers
- Accepted
Summary
This study is designed to evaluate dose-proportionality of Dilatrend SR 8mg, 16mg, 32mg, 64mg, 128mg in healthy male volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dilatrend SR capsule | single oral administration in period 1 or 2, 3 for each sequential group. |
Timeline
- Start date
- 2011-06-01
- Primary completion
- 2011-10-01
- Completion
- 2011-10-01
- First posted
- 2011-06-09
- Last updated
- 2012-02-15
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT01369472. Inclusion in this directory is not an endorsement.